#PrecisionMedicine company, empowering #oncologists with personalized treatment options for patients with #cancer
San Diego, CA
Joined November 2015
- Tweets900
- Following2.9K
- Followers1.4K
- Likes814
Pinned Tweet
๐ Our landmark study in npj Genomic Medicine shows better outcomes when cancer biology is well-matched:ย survival doubled (OS 18.7 vs 9.0 mo; HR 0.54, P=0.003) in multivariate analysis validating @CureMatch Score๐Link in comments
Study of 540 advanced cancer patients links CureMatch's Molecular Matching Score to doubled overall survival and tripled progression-free survival.
We have an amazing team led by @Dr_R_Kurzrock @AllyPerlina @NavidAlipour
einpresswire.com/article/948โฆ
This peer-reviewed paper marks our strongest clinical validation to date and a critical milestone for the oncology community.
Our esteemed cofounder, @Dr_R_Kurzrock at the @WIN_Consortium symposium. The 9 headed hydra slide, epitomizes what we do!
CureMatch retweeted
๐ฅ๐ฒ๐ด๐ถ๐๐๐ฒ๐ฟ ๐ป๐ผ๐: bit.ly/WINSympo2026website
๐ง๐ต๐ฒ ๐ฐ๐ผ๐๐ป๐๐ฑ๐ผ๐๐ป ๐ถ๐ ๐ผ๐ป ๐ณ๐ผ๐ฟ ๐ช๐๐ก ๐ฆ๐๐บ๐ฝ๐ผ๐๐ถ๐๐บ ๐ฎ๐ฌ๐ฎ๐ฒ.
How are AI, genomic profiling and next-generation therapeutics changing the future of precision oncology?
The Industry Perspectives program brings together leaders from across life sciences to explore emerging technologies, novel drug targets and industry-academia collaboration.
๐๐ ๐ฎ๐ป๐ฑ ๐๐ต๐ฒ ๐๐ต๐ฎ๐ป๐ด๐ถ๐ป๐ด ๐๐ฟ๐ผ๐ป๐๐ถ๐ฒ๐ฟ ๐ผ๐ณ ๐ฃ๐ฟ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป ๐ ๐ฒ๐ฑ๐ถ๐ฐ๐ถ๐ป๐ฒ
> Dr. David Spetzler, MS, PhD, MBA - Caris Life Sciences, Paradise Valley, AZ, USA
Followed by:
๐๐ป๐ฑ๐๐๐๐ฟ๐ ๐ฃ๐ฒ๐ฟ๐๐ฝ๐ฒ๐ฐ๐๐ถ๐๐ฒ๐: ๐๐ฒ๐ป๐ผ๐บ๐ถ๐ฐ ๐ฃ๐ฟ๐ผ๐ณ๐ถ๐น๐ถ๐ป๐ด, ๐ก๐ฒ๐
๐-๐๐ฒ๐ป๐ฒ๐ฟ๐ฎ๐๐ถ๐ผ๐ป ๐๐ฟ๐๐ด๐ & ๐ฃ๐ฟ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป ๐ข๐ป๐ฐ๐ผ๐น๐ผ๐ด๐
Featuring:
> Mr. Zach Boyd, MS, PhD - J&J, Thousand Oaks, CA, USA
> Mr. John Tarantino, JD - Iylon, USA
> Dr. David Spetzler, MS, PhD, MBA - Caris Life Sciences, Paradise Valley, AZ, USA
> Mr. Navid Alipour, JD/MBA - CureMatch, USA
> Prof. Nesrin Erkol, PhD - Vaccizone Biotechnology, Turkey
> Mr. Bradley Sander - P53 Therapeutics, USA
> Dr. Emile Youssef, MD, PhD - P53 Therapeutics, USA
Join the international precision oncology community in ๐ฃ๐ฟ๐ผ๐๐ถ๐ฑ๐ฒ๐ป๐ฐ๐ฒ, ๐ฅ๐ต๐ผ๐ฑ๐ฒ ๐๐๐น๐ฎ๐ป๐ฑ, ๐ข๐ฐ๐๐ผ๐ฏ๐ฒ๐ฟ ๐ฎ-๐ฏ, ๐ฎ๐ฌ๐ฎ๐ฒ.
โณ Register now and be part of the conversation.
#WINSympo2026 #PrecisionOncology #CancerResearch #AIinHealthcare #Genomics #LifeSciences
๐ Read the full open-access study here:ย nature.com/articles/s41525-0โฆ
The hard work put in every day, by so many to deliver better clinical decision support, with our amazing cofounder @Dr_R_Kurzrock blazing a path to prolong lives and save lives. This is TRUE precision medicine. Each cancer is molecularly unique.
linkedin.com/posts/precisionโฆ
CureMatch retweeted
So incredibly proud of our @CureMatch team! The hard work put in every day, by so many to deliver better clinical decision support, with our amazing cofounder @Dr_R_Kurzrock blazing a path to prolong lives and save lives.
linkedin.com/posts/precisionโฆ
CureMatch retweeted
Bringing experts together from across the nation to help rare cancer patients
Have you ever wondered what takes place in a TCF-001 TRACK Virtual #MolecularTumorBoard meeting?
Watch to learn how biomarker testing and multi-disciplinary expertise come together to uncover treatment options for difficult-to-treat #RareCancers
targetcancer.short.gy/RCTT-2โฆ
CureMatch retweeted
We've officially announced the next evolution of #cmAngioยฎ. Building on FDA-cleared BAC detection, cmAngio now detects, quantifies & contextualizes Breast Arterial Calcification (BAC). New: BAC quantification, Age-Based Percentile & Prevalence.
einpresswire.com/article/934โฆ
What if cancer treatment could be lethal to the tumorโbut not the patient?
Clinical and multi-omics data now reveal each cancerโs unique hallmarks and drivers.
At CureMatch, we transform complex molecular profiles into ranked, personalized combination options so oncologists can deliver more precise care.
Precision medicine isnโt the future.
Itโs happening now.
#PrecisionOncology #MultiOmics #PersonalizedMedicine #CureMatch
This insight enables highly targeted therapies that attack the disease while sparing healthy tissueโimproving efficacy and reducing harm.
Pancreatic cancer remains one of the deadliest malignancies. Uncovering its molecular drivers is critical.
CureMatch helps ranks, genomically matched combination therapies to help oncologists target them. #PancreaticCancer #PrecisionMedicine
Rare cancers foreshadow the future of precision oncology. As molecular characterization becomes increasingly comprehensive, classification based on tissue of origin or single biomarkers gives way to recognition that each tumor possesses a unique and complex molecular identity.
โThe N-of-1 paradigm reframes cancer as requiring customized therapeutic solutions. Future advances will depend not only on new drugs but also on validating sophisticated matching algorithms capable of delivering truly personalized cancer care.โ From our cofounder @Dr_R_Kurzrock
CureMatch retweeted
One gene/one target has a ceiling in complex cancers. Either treat earlier before complex evolution or give biomarker matched combinations or both
Pleasure to work with @VivekSubbiah on this concept
โญ๏ธPleased to share our paper ๐๐ผBeyond one gene, one target: Next-generation precision oncology: Trends in Cancer @trendscancer @CellCellPress @CellPressNews @OncoAlert @Dr_R_Kurzrock
cell.com/trends/cancer/fulltโฆ
